Arbutus Biopharma Corp

ABUS.US
Healthcare · Biotechnology
4.41
+0.00 (+0.00%)
USD · NASDAQ

Company Information

Company Name
Arbutus Biopharma Corp
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: CA03879J1003
CIK: 0001447028
CUSIP: 87911B209
Currency: USD
Full Time Employees: 19
Phone: 267 469 0914
Fiscal Year End: December
IPO Date: Aug 03, 2015
Description:

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Address:

701 Veterans Circle, Warminster, PA, United States, 18974

People

Directors & Officers

Name Title Year Born
Ms. Lindsay Androski J.D., M.B.A. President, CEO & Chairman 1977
Mr. Tuan Nguyen Chief Financial Officer 1976
Mr. Andrew J. Sung General Counsel NA
Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. Corporate Secretary 1951

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 09, 2021 Michael J Mcelhaugh N/A Sale 20.00K $5.00 $100.00K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Morgan Stanley - Brokerage Accounts 25.89M Mar 31, 2026 13.11% $0.01 -3.04%
Two Seas Capital LP 18.56M Mar 31, 2026 9.39% $1.17 47.41%
Whitefort Capital Management, LP. 14.93M Mar 31, 2026 7.56% $19.81 11.90%
BlackRock Inc 12.97M Mar 31, 2026 6.56% $0.00 -0.66%
Vanguard Group Inc 9.24M Dec 31, 2025 4.68% $0.00 2.80%
Vanguard Capital Management, LLC 6.69M Mar 31, 2026 3.39% $0.00 0.00%
Rubric Capital Management LP 6.63M Mar 31, 2026 3.35% $0.32 320.62%
State Street Corp 6.34M Mar 31, 2026 3.21% $0.00 7.35%
Barclays PLC 4.32M Mar 31, 2026 2.18% $0.00 1,110.06%
Geode Capital Management, LLC 3.77M Mar 31, 2026 1.91% $0.00 2.57%
ADAR1 Capital Management LLC 3.13M Mar 31, 2026 1.59% $0.83 -42.14%
Adage Capital Partners Gp LLC 2.66M Mar 31, 2026 1.35% $0.02 -38.60%
BlackBarn Capital Partners LP 2.50M Mar 31, 2026 1.27% $0.91 35.14%
Legal & General Group PLC 2.40M Mar 31, 2026 1.22% $0.00 1,856.15%
Woodline Partners LP 2.01M Mar 31, 2026 1.02% $0.03 -8.07%
Jefferies Financial Group Inc 1.89M Mar 31, 2026 0.96% $0.06 0.00%
Bank of America Corp 1.68M Mar 31, 2026 0.85% $0.00 -8.13%
Charles Schwab Investment Management Inc 1.40M Mar 31, 2026 0.71% $0.00 -10.31%
Vanguard Portfolio Management, LLC 1.39M Mar 31, 2026 0.70% $0.00 0.00%
Advisor Group Holdings, Inc. 1.35M Mar 31, 2026 0.68% $0.01 -0.01%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 5.03M 2.55% ▲ 4.63% Jun 30, 2026
2 iShares Russell 2000 ETF 4.13M 2.09% ▲ 0.60% Jun 30, 2026
3 Morgan Stanley Insight I 3.83M 1.94% ▼ 2.59% Mar 31, 2026
4 Morgan Stanley Insight 3.83M 1.94% ▼ 2.59% Mar 31, 2026
5 State Street® SPDR® S&P® Biotech ETF 3.66M 1.85% ▼ 2.18% Jun 30, 2026
6 MS INVF Global Insight Z 2.50M 1.27% ▲ 0.00% Mar 31, 2026
7 Morgan Stanley Inception 2.03M 1.03% ▼ 5.66% Mar 31, 2026
8 Morgan Stanley Inst Inception I 2.03M 1.03% ▼ 5.66% Mar 31, 2026
9 Vanguard Institutional Extnd Mkt Idx Tr 1.81M 0.92% ▲ 3.69% Jun 30, 2026
10 Fidelity Small Cap Index 1.50M 0.76% ▲ 0.89% Apr 30, 2026

Financial Highlights

Market Cap: $871.14M
EBITDA: $155.14M
P/E Ratio: $5.31
PEG Ratio: $0.00
Book Value: $1.32
Earnings/Share: $0.83
Profit Margin: 83.95%
Operating Margin: 94.41%
ROA (TTM): 49.18%
ROE (TTM): 94.73%
Revenue (TTM): $191.44M
Revenue/Share (TTM): $1.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 10,054.50%

Valuation Metrics

Enterprise Value: $776.55M
Trailing P/E: 5.31
Forward P/E: 10.25

Shares Statistics

Shares Outstanding: 197.54M
Shares Float: 122.89M
% Insiders: 2,045.90%
% Institutions: 7,201.00%
Short % Float: 14.80%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$14.08M
Cost of Goods Sold
adjust
$-363.00K
Gross Profit
subtotal
$13.72M
SG&A
adjust
$-15.89M
R&D
adjust
$-25.24M
Operating Income
subtotal
$-27.05M
Other / Non-Operating Items
adjust
$-6.45M
Net Income
subtotal
$-33.50M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ABUS.US!